The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Clonal Hematopoiesis (CHIP)

Clonal hematopoiesis of indeterminate potential and its clinical significance

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Clonal Hematopoiesis (CHIP)?

Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the presence of somatic mutations associated with hematologic malignancy (variant allele frequency at or above 2 percent) in peripheral blood without an overt hematologic cancer or cytopenia. The most frequent mutations involve DNMT3A, TET2, and ASXL1 and become more common with age.

CHIP carriers have an annual risk of progression to a hematologic malignancy such as MDS or AML of roughly 0.5 to 1 percent. More strikingly, CHIP increases cardiovascular disease risk by 1.5 to 2 fold, with shifts in inflammatory cytokine signaling thought to underlie this effect.

CHIP is usually identified incidentally on next-generation sequencing performed for other indications. Management guidelines recommend periodic hematologic surveillance, aggressive cardiovascular risk-factor control, and patient counseling. There is no indication for active treatment, but clonal evolution should be monitored.

Symptoms

CHIP is generally asymptomatic
Detected incidentally as a genetic test finding
Increased risk of therapy-related MDS or AML after chemotherapy
Higher risk of cardiovascular events
Elevated chronic inflammatory markers

Risk Factors

Older age (10 to 20 percent of those over 65)
Previous chemotherapy or radiotherapy
Smoking
Chronic inflammatory conditions

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When CHIP mutations are identified on NGS, a hematology consultation is appropriate
  • If unexplained cytopenia develops
  • For cardiovascular risk assessment

Treatment Methods

01
No active treatment is indicated
02
Annual complete blood count and peripheral smear surveillance
03
Cardiovascular risk-factor control
04
Closer monitoring after prior chemotherapy
05
Tracking clonal evolution (rising VAF, new mutations)
06
Patient education and genetic counseling

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.